For example, by next-generation sequencing of castrate-resistant prostate cancer (CRPC), Collins et al. [34] identified a homozygous 9p21 deletion spanning the MTAP, CDKN2, and ARF genes and deficiency of MTAP was suggested as an exploitable tumor target. Here, CDKN2A is linked to neoplasm.